Ngm Biopharmaceuticals Inc Quick Ratio (NGM) starting from the fourth quarter 2023 to fourth quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Ngm Biopharmaceuticals Inc   (NASDAQ: NGM)

Ngm Biopharmaceuticals Inc 's Quick Ratio

NGM's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2023, Quick Ratio deteriorated to 7.18 below Ngm Biopharmaceuticals Inc 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 56 other companies have achieved higher Quick Ratio than Ngm Biopharmaceuticals Inc in fourth quarter 2023. While Quick Ratio total ranking in the fourth quarter 2023 has deteriorated compared to the prior quarter from 98 to 293.

Explain Quick Ratio?
How much Cash & cash equivalents NGM´s has?
What are NGM´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NGM Quick Ratio (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4
Y / Y Current Liabilities Change -58.03 % -54.02 % -33.18 % -14.95 % -45.15 %
Y / Y Cash & cash equivalent Change -46.89 % -44.68 % -35.01 % -29.96 % -25.87 %
Quick Ratio MRQ 7.18 7.43 6.81 6.09 5.67
NGM's Total Ranking # 293 # 98 # 505 # 245 # 379
Seq. Current Liabilities Change -10.13 % -21.38 % -25.01 % -20.77 % -1.55 %
Seq. Cash & cash equivalent Change -13.17 % -14.21 % -16.22 % -14.91 % -9.55 %



Quick Ratio fourth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 57
Healthcare Sector # 104
Overall Market # 293


Quick Ratio Statistics
High Average Low
17.07 8.76 5.67
(Jun 30 2019)   (Dec 31 2022)




Financial Statements
Ngm Biopharmaceuticals Inc 's Current Liabilities $ 20 Millions Visit NGM's Balance sheet
Ngm Biopharmaceuticals Inc 's Cash & cash equivalent $ 144 Millions Visit NGM's Balance sheet
Source of NGM's Sales Visit NGM's Sales by Geography


Cumulative Ngm Biopharmaceuticals Inc 's Quick Ratio

NGM's Quick Ratio for the trailling 12 Months

NGM Quick Ratio

 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months
Y / Y Current Liabilities TTM Growth -40.75 % -38.76 % -25.94 % -18.6 % -13.85 %
Y / Y Cash & cash equivalent TTM Growth -38.73 % -33.38 % -27.67 % -25.14 % -22.77 %
Quick Ratio TTM 6.76 6.32 6.12 6.22 6.53
Total Ranking TTM # 3483 # 3490 # 373 # 1670 # 2906
Seq. Current Liabilities TTM Growth -20.34 % -16.13 % -7.98 % -3.63 % -17.67 %
Seq. Cash & cash equivalent TTM Growth -14.77 % -13.46 % -9.47 % -8.24 % -7.32 %

Quick ratio ranking by company, industry and sector >> Back to NGM Financial Strength Comparisons >> Go to Compare NGM Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Ngm Biopharmaceuticals Inc 's average Cash & cash equivalent, this led to increase in in Ngm Biopharmaceuticals Inc 's Quick Ratio to 6.76, Quick Ratio remained below NGM average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 462 other companies have achieved higher Quick Ratio than Ngm Biopharmaceuticals Inc . While Quick Ratio overall ranking has improved so far to 3483, from total ranking during the twelve months ending third quarter 2023 at 3490.

Explain Quick Ratio?
How much Cash & cash equivalents NGM´s has?
What are NGM´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 463
Healthcare Sector # 923
Within the Market # 3483


trailing twelve months Quick Ratio Statistics
High Average Low
9.45 7.59 6.12
(Mar 31 2020)   (Jun 30 2023)




Companies with similar Quick Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2023 MRQ Cash & cash equivalentDec 31 2023 MRQ Current Liabilities
Rezolute Inc   19.60 $ 101.896  Millions$ 5.200  Millions
Diamedica Therapeutics Inc   19.57 $ 52.895  Millions$ 2.703  Millions
89bio Inc   19.55 $ 578.870  Millions$ 29.611  Millions
Lantern Pharma Inc   19.25 $ 51.555  Millions$ 2.678  Millions
Viking Therapeutics Inc   19.25 $ 362.079  Millions$ 18.811  Millions
Edgewise Therapeutics inc   18.98 $ 318.393  Millions$ 16.771  Millions
Disc Medicine Inc   18.53 $ 360.382  Millions$ 19.453  Millions
Structure Therapeutics Inc   18.24 $ 467.323  Millions$ 25.617  Millions
Rapport Therapeutics Inc   18.13 $ 147.478  Millions$ 8.133  Millions
Dianthus Therapeutics Inc   18.04 $ 173.718  Millions$ 9.631  Millions
Atea Pharmaceuticals Inc   17.86 $ 578.106  Millions$ 32.376  Millions
Fulcrum Therapeutics Inc   17.27 $ 236.221  Millions$ 13.675  Millions
Neurogene Inc   17.00 $ 390.494  Millions$ 22.973  Millions
Sagimet Biosciences inc   16.98 $ 94.897  Millions$ 5.589  Millions
Atossa Therapeutics Inc   16.92 $ 88.570  Millions$ 5.236  Millions
Verve Therapeutics Inc   16.86 $ 623.950  Millions$ 37.006  Millions
Contineum Therapeutics Inc   16.49 $ 125.190  Millions$ 7.594  Millions
Protagonist Therapeutics inc   16.06 $ 341.617  Millions$ 21.274  Millions
Lyell Immunopharma Inc   15.82 $ 546.223  Millions$ 34.519  Millions
Boundless Bio Inc   15.75 $ 239.535  Millions$ 15.212  Millions
Relmada Therapeutics Inc  15.46 $ 188.556  Millions$ 12.195  Millions
Savara Inc   15.32 $ 162.319  Millions$ 10.597  Millions
Nanoviricides inc   15.25 $ 8.150  Millions$ 0.534  Millions
Alto Neuroscience Inc   14.71 $ 82.548  Millions$ 5.610  Millions
Greenwich Lifesciences Inc   14.65 $ 6.989  Millions$ 0.477  Millions
Hoth Therapeutics Inc   14.30 $ 9.292  Millions$ 0.650  Millions
Trevi Therapeutics Inc   14.25 $ 82.971  Millions$ 5.824  Millions
Bullfrog Ai Holdings Inc   14.23 $ 2.625  Millions$ 0.184  Millions
Kinnate Biopharma Inc   13.87 $ 154.034  Millions$ 11.103  Millions
Mbx Biosciences Inc   13.71 $ 80.726  Millions$ 5.887  Millions

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.